Brain­storm backs off a con­tro­ver­sial plan to sell its ex­per­i­men­tal ALS med, but this is­sue is far from over

Brain­storm Cell Ther­a­peu­tics $BCLI won’t be an­gling to make any prof­its off the new ‘Right to Try’ bill af­ter all.

Af­ter stir­ring or hor­net’s nest of an­gry Twit­ter memes af­ter Bloomberg quot­ed CEO Chaim Lebovits say­ing that they were prepar­ing to sell their drug to des­per­ate ALS pa­tients, in­clud­ing one who lent his name to the leg­is­la­tion, the mi­cro-cap biotech this morn­ing is back­ing off the idea.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER